Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies.

ABSTRACT:

Background

Plasmodium vivax is the most widespread human malaria geographically; however, no effective vaccine exists. Red blood cell invasion by the P. vivax merozoite depends on an interaction between the Duffy antigen receptor for chemokines (DARC) and region II of the parasite's Duffy-binding protein (PvDBP_RII). Naturally acquired binding-inhibitory antibodies against this interaction associate with clinical immunity, but it is unknown whether these responses can be induced by human vaccination.

Methods

Safety and immunogenicity of replication-deficient chimpanzee adenovirus serotype 63 (ChAd63) and modified vaccinia virus Ankara (MVA) viral vectored vaccines targeting PvDBP_RII (Salvador I strain) were assessed in an open-label dose-escalation phase Ia study in 24 heal

SUBMITTER: Payne RO 

PROVIDER: S-EPMC5470884 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature